NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of NeuroPace, Inc. (NASDAQ:NPCE) have been assigned an average rating of “Moderate Buy” from the seven ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $14.50.

A number of research analysts recently commented on the stock. Wells Fargo & Company lowered their price target on shares of NeuroPace from $15.00 to $13.00 and set an “overweight” rating for the company in a report on Wednesday, November 13th. JPMorgan Chase & Co. raised their price objective on NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th.

Insider Buying and Selling

In other NeuroPace news, major shareholder Ltd. Kck sold 223,991 shares of the company’s stock in a transaction on Friday, October 25th. The stock was sold at an average price of $5.45, for a total value of $1,220,750.95. Following the transaction, the insider now owns 5,270,845 shares of the company’s stock, valued at $28,726,105.25. This represents a 4.08 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold 257,590 shares of company stock valued at $1,437,916 in the last ninety days. 22.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On NeuroPace

A number of institutional investors have recently modified their holdings of NPCE. Rhumbline Advisers bought a new position in shares of NeuroPace during the 2nd quarter worth $111,000. Financial Advocates Investment Management lifted its stake in NeuroPace by 50.0% in the second quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock worth $113,000 after acquiring an additional 5,000 shares during the period. Barclays PLC lifted its stake in NeuroPace by 346.0% in the third quarter. Barclays PLC now owns 20,633 shares of the company’s stock worth $144,000 after acquiring an additional 16,007 shares during the period. XTX Topco Ltd grew its holdings in NeuroPace by 56.1% during the 2nd quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock worth $182,000 after acquiring an additional 8,643 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in NeuroPace during the 2nd quarter valued at about $257,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

NeuroPace Stock Performance

NASDAQ:NPCE opened at $11.14 on Friday. The company has a market cap of $332.51 million, a price-to-earnings ratio of -11.14 and a beta of 2.05. NeuroPace has a 1 year low of $5.45 and a 1 year high of $18.15. The stock’s 50 day simple moving average is $8.91 and its two-hundred day simple moving average is $7.76. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The company had revenue of $21.06 million for the quarter, compared to analysts’ expectations of $19.33 million. During the same quarter in the previous year, the business posted ($0.28) earnings per share. As a group, equities analysts anticipate that NeuroPace will post -1 earnings per share for the current fiscal year.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.